Luminex Corp. (LMNX) Tops Q4 Views

Luminex Corp. (NASDAQ: LMNX) reported Q4 EPS of $0.56, which may not compare to the analyst estimate of $0.15. Revenue for the quarter came in at $60.4 million versus the consensus estimate of $60.21 million.

"In 2015, Luminex achieved all of its major product development and regulatory milestones, including FDA clearances of the NxTAG RPP assay, the ARIES sample to answer molecular system, and the ARIES HSV1&2 assay, as well as our initial goal of placing 30 ARIES systems. We generated solid financial results for the year, achieving record revenue of $238 million, gross margins of 71% and generated over $40 million of cash flow," said Homi Shamir, President and Chief Executive Officer of Luminex. "Moving forward, we will continue to leverage our balanced business model and strong financial position to accelerate future revenue and earnings growth. In addition, we are focused on executing a successful market introduction of ARIES, which we anticipate will accelerate over time with the expansion of available ASR products and FDA clearance for additional assays. In addition, we continue to make good progress with our next-generation ARIES chemistry and expect to have a first assay enter clinical trials in the second half of 2017. With exciting new products on the market and strong cash flow, we are excited to build on our solid performance in 2015. We look forward to another successful year ahead."

For earnings history and earnings-related data on Luminex Corp. (LMNX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SanDisk upgraded at JPMorgan after investor day; shares climb
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49